Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Inclusion Criteria: * Mother is able to provide written informed consent for her and her infant's participation in this study * Mother has confirmed HIV-1 infection based on documented testing of two samples collected at different time points: * Sample #1 may be tested using any of the following: * Two rapid antibody tests from different manufacturers or based on different principles and epitopes * One enzyme immunoassay (EIA) OR Western blot OR immunofluorescence assay OR chemiluminescence assay * One HIV DNA polymerase chain reaction (PCR) * One quantitative HIV RNA PCR (above the limit of detection of the assay) * One qualitative HIV RNA PCR * One total HIV nucleic acid test * Sample #2 may be tested using any of the following: * One rapid antibody test. If this option is used in combination with two rapid tests for Sample #1, at least one of the three rapid tests must be FDA-approved and the third rapid test must be from a third manufacturer or based on a third principle or epitope. * One EIA OR Western blot OR immunofluorescence assay OR chemiluminescence assay * One HIV DNA PCR * One quantitative HIV RNA PCR (above the limit of detection of the assay) * One qualitative HIV RNA PCR * One total HIV nucleic acid test. * See the protocol for more information on this inclusion criterion. * At screening, mother is ART-naive, defined as having not received prior antiretroviral therapy other than ARVs received during prior pregnancies or prior pe…